Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1...
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD...
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology...
122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology...
Eliminate data silos and streamline workflows to improve operational efficiencySAN DIEGO--(BUSINESS WIRE)--Seqster PDM, Inc. ("SEQSTER") , the industry leading patient-centric...
Eliminate data silos and streamline workflows to improve operational efficiencySAN DIEGO--(BUSINESS WIRE)--Seqster PDM, Inc. ("SEQSTER") , the industry leading patient-centric...
Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial...
To register for the webinar, click hereSAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a...
The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to...
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient...
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug...
WASHINGTON--(BUSINESS WIRE)--#parkerhealth--Parker Health, Inc, a prominent biotech company, is delighted to introduce Dr. Tushar Hazra as its new Chief Technology...
Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for...
Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for...
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is...
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is...
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company,...